Processa Pharmaceuticals, Inc. (PCSA) Gets FDA IND OK for VT-7208 Phase 2 in CSU

Processa Pharmaceuticals (PCSA) received FDA clearance for a Phase 2 study of VT-7208 in chronic spontaneous urticaria. The company plans additional Phase 2 studies for food allergy and relapsing multiple sclerosis. Processa also announced a collaboration with Generian and the appointment of Sheila Gujrathi as Executive Chair. The company expects cash resources to last until mid-2029 after a $200 million private placement.

Processa Pharmaceuticals, Inc. (PCSA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Processa Pharmaceuticals Announces Corporate and Pipeline Progress Following Acquisition of Vidya Therapeutics • U.S. FDA clears IND for Phase 2 study of VT-7208 in chronic spontaneous urticaria ; additional Phase 2 studies planned in food allergy and relapsing multi

Processa Pharmaceuticals (PCSA) received FDA clearance for a Phase 2 study of VT-7208 in chronic spontaneous urticaria. The study will enroll 120 adults and evaluate the drug's efficacy, safety, and tolerability. The company also announced a collaboration with Generian Pharmaceuticals and appointed Sheila Gujrathi as Executive Chair. Processa expects its cash resources to support operations into the second half of 2029.

Processa Pharmaceuticals (Nasdaq: PCSA) completed a July 2026 acquisition of Vidya Therapeutics, adding CNS-penetrant BTK inhibitor VT-7208 and shifting focus to immune-mediated diseases. Vidya holders received about 46% and private placement investors about 52.6%, leaving prior Processa holders about 0.9%. A $200M private placement funds operations into 2H 2029; Phase II starts planned in 2H 2026 (food allergy, CSU) and 1H 2027 (RMS).

The healthcare sector saw multiple company-specific moves. Pfizer and BioNTech received EU approval for an updated COVID-19 vaccine targeting the XFG variant. Cipla won FDA approval for generic Advair Diskus, and Viatris gained FDA approval for its Gwyn Lo contraceptive patch. AbbVie’s Rinvoq was approved in the EU for non-segmental vitiligo. Boston Scientific announced an $800M restructuring plan, while GSK launched a $2.5B cost-saving program. J&J and Sail agreed a $3.51B CAR-T deal; Argenx ac

Processa Pharmaceuticals, Inc. (PCSA), a clinical-stage biotechnology company, has acquired privately held Vidya Therapeutics, Inc. and simultaneously raise approximately $200 million through a private financing. Vidya's lead candidate, VT-7208, is a next-generation CNS-penetrant Bruton's tyrosine kinase inhibitor (BTKi) being developed for immune-mediated diseases like food allergy, chronic spontaneous urticaria (CSU), and relapsing multiple sclerosis (RMS).